{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:57:39Z","timestamp":1794650259631,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.urolonc.2023.11.018","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T02:24:00Z","timestamp":1705803840000},"page":"67.e9-67.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy"],"prefix":"10.1016","volume":"42","author":[{"given":"Binyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-5145","authenticated-orcid":false,"given":"Xuefeng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0001","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative Intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2023.11.018_bib0002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.6004\/jnccn.2019.0023","article-title":"Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Mohler","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0003","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: Report of the advanced prostate cancer consensus conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.11.018_bib0004","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/14737140.2021.1852932","article-title":"Current and emerging therapies for localized high-risk prostate cancer","volume":"21","author":"Moris","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.018_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/JU.0000000000001702","article-title":"Results of a randomized phase II trial of intense androgen deprivation therapy prior to radical prostatectomy in men with high-risk localized prostate cancer","volume":"206","author":"McKay","year":"2021","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.018_bib0006","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1097\/JU.0000000000001632","article-title":"Outcomes of post-neoadjuvant intense hormone therapy and surgery for high risk localized prostate cancer: Results of a pooled analysis of contemporary clinical trials","volume":"205","author":"McKay","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2023.11.018_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7819-10-1","volume":"10","author":"Narita","year":"2012","journal-title":"World J Surg Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.018_bib0008","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.18.01777","article-title":"Evaluation of intense androgen deprivation before prostatectomy: A randomized phase II trial of enzalutamide and leuprolide with or without abiraterone","volume":"37","author":"McKay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0009","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000001481","article-title":"Can (68)Ga-PSMA-11 positron emission tomography\/computerized tomography predict pathological response of primary prostate cancer to neoadjuvant androgen deprivation therapy? A pilot study","volume":"205","author":"Chen","year":"2021","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.018_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: Prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0011","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/pros.23130","article-title":"Histopathological features of intra-ductal carcinoma of prostatic and high grade prostatic intraepithelialneoplasia and correlation with PTEN and P63","volume":"76","author":"Torabi-Nezhad","year":"2016","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.018_bib0012","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12916-022-02430-0","article-title":"Homologous recombination deficiency (HRD) score in aggressive prostatic adenocarcinoma with or without intraductal carcinoma of the prostate (IDC-P)","volume":"20","author":"Zhu","year":"2022","journal-title":"BMC Med"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.018_bib0013","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pros.23326","article-title":"Intraductal carcinoma of the prostate on diagnostic needle biopsy predicts prostate cancer mortality: A population-based study","volume":"77","author":"Saeter","year":"2017","journal-title":"Prostate."},{"issue":"15","key":"10.1016\/j.urolonc.2023.11.018_bib0014","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/pros.24215","article-title":"The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer","volume":"81","author":"Wang","year":"2021","journal-title":"Prostate"},{"issue":"33","key":"10.1016\/j.urolonc.2023.11.018_bib0015","doi-asserted-by":"crossref","first-page":"55374","DOI":"10.18632\/oncotarget.19520","article-title":"The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy","volume":"8","author":"Zhao","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.urolonc.2023.11.018_bib0016","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bju.14970","article-title":"Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate","volume":"125","author":"Yamamoto","year":"2020","journal-title":"BJU Int"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.018_bib0017","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.crad.2019.03.016","article-title":"Prostate biopsy: When and how to perform","volume":"74","author":"Das","year":"2019","journal-title":"Clin Radiol"},{"key":"10.1016\/j.urolonc.2023.11.018_bib0018","series-title":"WHO classification of tumours: Urinary and male genital","year":"2022"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.018_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euo.2018.03.013","article-title":"Features and prognostic significance of intraductal carcinoma of the prostate","volume":"1","author":"Montironi","year":"2018","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.018_bib0020","doi-asserted-by":"crossref","first-page":"938","DOI":"10.5858\/arpa.2018-0005-RA","article-title":"Spectrum of cribriform proliferations of the prostate: From benign to malignant","volume":"142","author":"Lee","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.018_bib0021","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/pros.1117","article-title":"Patterns of spread of adenocarcinoma in the prostate as related to cancer volume","volume":"49","author":"McNeal","year":"2001","journal-title":"Prostate"},{"issue":"33","key":"10.1016\/j.urolonc.2023.11.018_bib0023","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0024","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eururo.2019.05.010","article-title":"Clinical and biological characterisation of localised high-risk prostate cancer: Results of a randomised preoperative study of a luteinising hormone-releasing hormone agonist with or without abiraterone acetate plus prednisone","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.urolonc.2023.11.018_bib0025","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and leukemia group B 90203 (alliance): Radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.018_bib0026","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1007\/s00259-022-06047-6","volume":"50","author":"Ke","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.urolonc.2023.11.018_bib0027","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.acra.2019.10.017","article-title":"Multiparametric MRI as a biomarker of response to neoadjuvant therapy for localized prostate cancer-a pilot study","volume":"27","author":"Fennessy","year":"2020","journal-title":"Acad Radiol"},{"issue":"2","key":"10.1016\/j.urolonc.2023.11.018_bib0028","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1158\/1078-0432.CCR-20-2344","article-title":"Sequential prostate magnetic resonance imaging in newly diagnosed high-risk prostate cancer treated with neoadjuvant enzalutamide is predictive of therapeutic response","volume":"27","author":"Karzai","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.018_bib0029","doi-asserted-by":"crossref","first-page":"352.e25","DOI":"10.1016\/j.urolonc.2019.01.012","article-title":"mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy","volume":"37","author":"Gold","year":"2019","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.11.018_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/bju.15530","article-title":"Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate","volume":"129","author":"Zhao","year":"2022","journal-title":"BJU Int"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:28:18Z","timestamp":1761042498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923004167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1078143923004167"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}